Remdesivir (COVID 19) Market Research Report - Global Forecast till 2027

Global Remdesivir (COVID 19) Market: By Dosage (5mg, 10mg, 50mg, 100mg), By Distribution Channel (Hospitals, Drug stores, others) and Region (Americas, Europe, Asia-Pacific, Middle East & Africa) - Forecast to 2027

ID: MRFR/HC/8663-HCR | February 2021 | Region: Global | 101 pages

Please note that assessment period of report has been updated from 2018-2027 to 2020-2027. Cordially fill sample form for updated data.

Market Forecast

Global Remdesivir (COVID 19) Market is expected to hold a value of USD 10,119.99 Million by 2027 and is expected to register a growth of 31.2% from 2020 to 2027.

Market Synopsis

Remdesivir is an antiviral medication developed by biopharmaceutical company Gilead Sciences. It is administered via injection into a vein. In March 2020 a research performed by Gilead Sciences Inc. on 53 prospective COVID-19 patients showed signs of progress in 36 patients, about 68% of the total number of patients. WHO has guided the start of clinical trials for Remdesivir along with three other drugs found to be effective in COVID-19 therapy. The drug has now reached phase 3 of clinical trials and the world hopes it will emerge as a promising treatment for COVID 19. Following these positive trials, the Food and Drug Administration issued permission for the medication to treat Covid-19 for emergency use authorization (EUA). That means the medication has not undergone the same examination as therapies approved by the FDA, but it will allow doctors to prescribe Remdesivir to patients hospitalized with the disease. All supply of drugs will go to the government for allocation across the nation.


  • Rising geriatric population

  • Increasing prevalence of Covid-19

    • In July 2020, 1.19 million COVID 19 cases are being recorded reason increasing demand for remdesivir globally

  • Can be used for other chronic diseases


  • Intense competition among industries

  • Government intervention


By Dosage

The Remdesivir drug is being used as an emergency drug for the treatment of COVID 19. Different doses are being given to the patients according to the age groups and weight but mainly 100 mg dosage dominating the remdesivir market globally.

  • 5mg: for pediatric patients weighing 3.5 kg to less than 40 kg, use remdesivir for injection, 100 mg, and lyophilized powder only.

  •  10 mg: 10 mg dosage was firstly used on rhesus monkeys before human beings using IV bolus injection initiated 12 hours post-inoculation with SARS-CoV-2 resulted in a reduction in clinical signs of respiratory disease, lung pathology, and gross lung lesions, and lung viral RNA levels compared with vehicle-treated animals.

  • 100mg: The recommended dosage of remdesivir for pediatric patients weighing 40 kg and higher is the adult dosage regimen of a single loading dose of 200 mg on Day 1 followed by once-daily maintenance doses of 100 mg from Day 2.

By Distribution Channel

  • Hospitals: While distribution is being handled by a commercial drug distributor, decisions regarding which hospitals get the drug have been left to government authorities. The drug is an infusion and will not be given to retail and specialty pharmacies. The distribution of remdesivir has been authorized only for the treatment of hospitalized patients with severe COVID-19. It is not authorized for the treatment of any other viruses or pathogens.

  • Drug stores: The government has not permitted drug stores to sell the remdesivir drug in the market. The drug is only being given in hospitals directly from manufacturers. Depending upon the success rate and side effects the drug can be approved in the drug store for the sale.

By Region

  • Americas: North America is projected to dominate the global Remdesivir market during the forecast period. In addition, the drug manufacturer Gilead Sciences is also headquartered in California, United The experimental drug received an emergency use authorization from the Food and Drug Administration last week after preliminary data from a clinical trial showed that it reduced how long it took hospitalized Covid-19 patients to recover. Now, as the drug’s producer, Gilead Sciences, tries to ramp up production, in the U.S.

  • Europe: Europe is projected to witness substantial growth in the overall demand for Remdesivir throughout the forecast period due to EMA's recommendation for the use of Remdesivir in compassionate COVID-19 care.

  • Asia-pacific: The Asia-Pacific market is also projected to see substantial growth due to the widespread use of the medication for COVID-19 treatment in countries such as China, Japan, among others. Additionally, the Indian Council of Medical Research has recently asked the major market players operating in the Indian pharmaceutical market to manufacture the drug and Dr. Reddy Laboratories has already started working on its generic form,”

  • Middle East and Africa: The Middle East and Africa are one of the fastest-growing markets due to the rise in COVID 19 cases. Gilead Sciences, Inc. tied up with Egypt’s pharma company and UAE pharma companies as well to manufacture the remdesivir drug to meet the shortage of drugs in the region.

Key Players

  • Gilead Sciences, Inc. (US)

  • Mylan (US)

  • Cipla (India)

  • Hetero Labs (India)

  • Jubilant Life Sciences (India)

Report Scope:
Report Attribute/Metric Details
  Market Size   2027: USD 10,119.99 Million
  CAGR   31.2% (2020-2027)
  Base Year   2019
  Forecast Period   2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Dosage, Distribution Channel
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Gilead Sciences, Inc. (US), Mylan (US), Cipla (India), Hetero Labs (India), and Jubilant Life Sciences (India)
  Key Market Opportunities

  • Rising geriatric population.
  • Increasing prevalence of Covid-19
  •   Key Market Drivers   Intense competition among industries

    This table of content is tentative and subject to change as the research progresses.

    Please Note:  Financial details of company cannot be provided if the information of the company is not available in public domain and or reliable source.